A
Amathus Therapeutics
Advancing treatment options for Parkinson’s and Polycystic Kidney Disease through targeted therapeutic development
About Amathus Therapeutics
Amathus Therapeutics, established in 2016, is a biopharmaceutical firm concentrated on developing treatments for neurodegenerative and renal diseases. The company's scientific foundation is built upon discoveries licensed from the Icahn School of Medicine at Mount Sinai, specifically from the laboratory of Professor Yiannis A. Ioannou. Initially founded and funded by Sanofi Ventures, the corporate venture capital arm of Sanofi, and the Dementia Discovery Fund, Amathus has secured its financial footing to pursue its research objectives.
The company's core business revolves around its proprietary drug discovery platform, which develops small-molecule therapeutics designed to modulate organelle-specific chaperones. This approach targets the body's cellular stress response pathways to rescue key cellular functions associated with genetically defined diseases. The primary focus is on conditions such as Parkinson's Disease, particularly related to the PINK1 gene, and Autosomal Dominant Polycystic Kidney Disease (ADPKD). Amathus' strategy involves identifying and advancing these novel chaperone activators through the preclinical discovery phase.
A significant milestone in the company's history was the establishment of a strategic collaboration with Merck in March 2021. This partnership provides Amathus with an upfront payment and leverages Merck's extensive resources for later-stage development. The terms of the agreement grant Merck an exclusive option to acquire Amathus and its entire pipeline of mitochondrial-targeted candidates. Should Merck exercise this option, Amathus is eligible for milestone payments potentially exceeding $500 million for each successful program, with Merck assuming full responsibility for clinical development and commercialization. This business model allows Amathus to focus on its expertise in early-stage discovery while providing a clear path to market through a major pharmaceutical partner.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Sector
- Biotech & Life Sciences
News
Open roles
Amathus Therapeutics in the Cambridge ecosystem
The Amathus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
SV Health Investors
Sanofi Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amathus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amathus Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

